Loading clinical trials...
Loading clinical trials...
Pharmacodynamic Effects and Predictive Biomarkers of Janus Kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Conditions
Interventions
Ruxolitinib
Locations
2
United States
University of Arizona Cancer Center
Tucson, Arizona, United States
University of California, San Francisco
San Francisco, California, United States
Start Date
June 8, 2018
Primary Completion Date
October 18, 2023
Completion Date
October 18, 2023
Last Updated
October 30, 2024
NCT06532279
NCT05910827
NCT05005403
NCT06992427
NCT05047094
NCT06163534
Lead Sponsor
University of California, San Francisco
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions